Century Therapeutics (IPSC) Cash & Current Investments (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash & Current Investments data on file, last reported at $134.8 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 18.36% year-over-year to $134.8 million in Q1 2026; TTM through Mar 2026 was $134.8 million, a 18.36% decrease from a year earlier, with the FY2025 full-year figure at $168.6 million, down 10.96% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $134.8 million, down from $168.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for IPSC reached as high as $378.8 million in Q2 2022 and fell as low as $132.7 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $217.3 million across 5 years, with a median of $189.3 million in 2024.
• Across the five-year window, Cash & Current Investments jumped 41.56% in 2022 and tumbled 58.71% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $315.5 million in 2022, then tumbled by 45.25% to $172.7 million in 2023, then grew by 9.58% to $189.3 million in 2024, then retreated by 10.96% to $168.6 million in 2025, then declined by 20.02% to $134.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $134.8 million in Q1 2026, $168.6 million in Q4 2025, and $132.7 million in Q3 2025.